Target intelligence / Profile preview

T cell receptor alpha joining 33 (TRAJ33)

Target
TRAJ33
Molecular classification
Other (J gene segment of immunoglobulin superfamily, not a receptor, enzyme, channel, transporter, or transcription factor)
01

Overview

TRAJ33 is a joining (J) gene segment in the human T cell receptor alpha locus (TRA), encoding part of the TCR alpha chain's variable region via somatic V(J) recombination. TRAJ33 is particularly important as the canonical J segment in the TCR alpha chains of MAIT (mucosal-associated invariant T) cells—an innate-like T cell population that recognizes vitamin B metabolites presented by MR1. MAIT cell TCRs typically use TRAV1-2 (V gene) paired with TRAJ33, forming a semi-invariant TCR necessary for their antigen recognition and development[4]. During T cell development, TRAJ33 recombines with variable segments to generate diversity and specificity in TCRs expressed on the surface of MAIT cells. TRAJ33 is not a protein product, receptor, transporter, or enzyme on its own, but a genetic segment required for the assembly of functional TCR alpha chains[3][4].\n\nIf you need structured data extraction for MAIT cell TCR, that would relate to the combined TRAV1-2/TRAJ33 TCR alpha chain usage, which constitutes a semi-invariant receptor crucial for MAIT cell biology[4]. However, TRAJ33 alone should be classified as a gene segment, not a receptor or therapeutic target.

Other names
TRAJ33T-cell receptor alpha J 33TCR J alpha 33
02

Biological functions

Generation of TCR diversity through V-J recombinationCritical for MAIT cell antigen recognition and developmentContribution to antigen-specific immune response (via its incorporation into the assembled TCR on specific T cells)
03

Disease associations

Infection (via MAIT cells recognizing microbial antigens)Other (potentially immune homeostasis and mucosal immunity)

Beyond the preview

Go deeper on T cell receptor alpha joining 33 (TRAJ33).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha joining 33 (TRAJ33).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call